Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Molecular basis and current strategies of therapeutic arginine depletion for cancer.

Fultang L, Vardon A, De Santo C, Mussai F.

Int J Cancer. 2016 Aug 1;139(3):501-9. doi: 10.1002/ijc.30051. Epub 2016 Apr 15. Review.

2.

Arginine deprivation in cancer therapy.

Feun LG, Kuo MT, Savaraj N.

Curr Opin Clin Nutr Metab Care. 2015 Jan;18(1):78-82. doi: 10.1097/MCO.0000000000000122. Review.

PMID:
25474015
3.
4.

The role of arginine and the modified arginine deiminase enzyme ADI-PEG 20 in cancer therapy with special emphasis on Phase I/II clinical trials.

Synakiewicz A, Stachowicz-Stencel T, Adamkiewicz-Drozynska E.

Expert Opin Investig Drugs. 2014 Nov;23(11):1517-29. doi: 10.1517/13543784.2014.934808. Epub 2014 Jun 26. Review.

PMID:
24965808
5.

Recombinant arginine-degrading enzymes in metabolic anticancer therapy and bioanalytics.

Stasyk OV, Boretsky YR, Gonchar MV, Sibirny AA.

Cell Biol Int. 2015 Mar;39(3):246-52. doi: 10.1002/cbin.10383. Epub 2014 Dec 3. Review.

PMID:
25231409
6.

Arginine-Depleting Enzymes - An Increasingly Recognized Treatment Strategy for Therapy-Refractory Malignancies.

Riess C, Shokraie F, Classen CF, Kreikemeyer B, Fiedler T, Junghanss C, Maletzki C.

Cell Physiol Biochem. 2018;51(2):854-870. doi: 10.1159/000495382. Epub 2018 Nov 22. Review.

7.

Arginine dependence of tumor cells: targeting a chink in cancer's armor.

Patil MD, Bhaumik J, Babykutty S, Banerjee UC, Fukumura D.

Oncogene. 2016 Sep 22;35(38):4957-72. doi: 10.1038/onc.2016.37. Epub 2016 Apr 25. Review.

8.
9.

Pegylated arginine deiminase: a novel anticancer enzyme agent.

Feun L, Savaraj N.

Expert Opin Investig Drugs. 2006 Jul;15(7):815-22. Review.

10.
11.

Recombinant human arginase inhibits proliferation of human hepatocellular carcinoma by inducing cell cycle arrest.

Lam TL, Wong GK, Chong HC, Cheng PN, Choi SC, Chow TL, Kwok SY, Poon RT, Wheatley DN, Lo WH, Leung YC.

Cancer Lett. 2009 May 8;277(1):91-100. doi: 10.1016/j.canlet.2008.11.031. Epub 2009 Jan 12.

PMID:
19138817
12.

Drug evaluation: ADI-PEG-20--a PEGylated arginine deiminase for arginine-auxotrophic cancers.

Shen LJ, Shen WC.

Curr Opin Mol Ther. 2006 Jun;8(3):240-8. Review.

PMID:
16774044
13.

Arginine deiminase, a potential anti-tumor drug.

Ni Y, Schwaneberg U, Sun ZH.

Cancer Lett. 2008 Mar 8;261(1):1-11. doi: 10.1016/j.canlet.2007.11.038. Epub 2008 Jan 7. Review.

PMID:
18179862
14.

Targeting arginine metabolism pathway to treat arginine-dependent cancers.

Qiu F, Huang J, Sui M.

Cancer Lett. 2015 Aug 1;364(1):1-7. doi: 10.1016/j.canlet.2015.04.020. Epub 2015 Apr 23. Review.

PMID:
25917076
15.

Arginine deprivation as a targeted therapy for cancer.

Feun L, You M, Wu CJ, Kuo MT, Wangpaichitr M, Spector S, Savaraj N.

Curr Pharm Des. 2008;14(11):1049-57. Review.

16.

Arginine Deiminase Enzyme Evolving as a Potential Antitumor Agent.

Somani RR, Chaskar PK.

Mini Rev Med Chem. 2018;18(4):363-368. doi: 10.2174/1389557516666160817102701. Review.

PMID:
27538511
17.

Arginine Metabolism in Bacterial Pathogenesis and Cancer Therapy.

Xiong L, Teng JL, Botelho MG, Lo RC, Lau SK, Woo PC.

Int J Mol Sci. 2016 Mar 11;17(3):363. doi: 10.3390/ijms17030363. Review.

18.

Anti-tumor activity of arginine deiminase via arginine deprivation in retinoblastoma.

Kim JH, Kim JH, Yu YS, Kim DH, Min BH, Kim KW.

Oncol Rep. 2007 Dec;18(6):1373-7.

PMID:
17982619
19.

Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target.

Mussai F, Egan S, Higginbotham-Jones J, Perry T, Beggs A, Odintsova E, Loke J, Pratt G, U KP, Lo A, Ng M, Kearns P, Cheng P, De Santo C.

Blood. 2015 Apr 9;125(15):2386-96. doi: 10.1182/blood-2014-09-600643. Epub 2015 Feb 20.

20.

Selective Intracellular Delivery of Recombinant Arginine Deiminase (ADI) Using pH-Sensitive Cell Penetrating Peptides To Overcome ADI Resistance in Hypoxic Breast Cancer Cells.

Yeh TH, Chen YR, Chen SY, Shen WC, Ann DK, Zaro JL, Shen LJ.

Mol Pharm. 2016 Jan 4;13(1):262-71. doi: 10.1021/acs.molpharmaceut.5b00706. Epub 2015 Dec 17.

Supplemental Content

Support Center